SCHEMBL1407101

SCHEMBL1407101

CC(=O)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 9/20 0.62
NR1H2 P55055 8/20 0.62
ALDH1A1 P00352 3/20 0.43
CYP19A1 P11511 1/20 0.42
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
POLB P06746 2/20 0.40
FABP4 P15090 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407373 0.90 NR1H3 (0.61) NR1H3NR1H2ALDH1A1CYP19A1POLB
SCHEMBL27730716 0.88 NR1H2 (0.59) NR1H3NR1H2ALDH1A1CYP19A1POLB
SCHEMBL1407853 0.87 NR1H3 (0.62) NR1H3NR1H2ALDH1A1CYP19A1TP53
SCHEMBL1407552 0.86 NR1H2 (0.58) NR1H3NR1H2ALDH1A1CYP19A1MAPT
SCHEMBL1408246 0.83 NR1H2 (0.54) NR1H3NR1H2ALDH1A1CYP19A1MAPT
SCHEMBL1408242 0.82 NR1H2 (0.53) NR1H3NR1H2CYP19A1TP53MAPT
SCHEMBL28770633 0.81 NR1H2 (0.58) NR1H3NR1H2ALDH1A1CYP19A1TP53
SCHEMBL1407734 0.80 NR1H3 (0.66) NR1H3NR1H2ALDH1A1CYP19A1POLB
SCHEMBL3862094 0.80 NR1H3 (0.69) NR1H3NR1H2ALDH1A1POLBLMNA
SCHEMBL28770635 0.80 NR1H3 (0.58) NR1H3NR1H2ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H3 2/4885NR1H2 1/4885ALDH1A1 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.